ZA202304779B - Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising thereof - Google Patents
Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising thereofInfo
- Publication number
- ZA202304779B ZA202304779B ZA2023/04779A ZA202304779A ZA202304779B ZA 202304779 B ZA202304779 B ZA 202304779B ZA 2023/04779 A ZA2023/04779 A ZA 2023/04779A ZA 202304779 A ZA202304779 A ZA 202304779A ZA 202304779 B ZA202304779 B ZA 202304779B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- chimeric protein
- binding domain
- receptor binding
- compositions
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title 1
- 101710132601 Capsid protein Proteins 0.000 abstract 3
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
| PCT/CU2021/050010 WO2022096039A1 (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304779B true ZA202304779B (en) | 2024-09-25 |
Family
ID=79164940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04779A ZA202304779B (en) | 2020-11-04 | 2023-04-25 | Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405106A1 (enExample) |
| EP (1) | EP4242222A1 (enExample) |
| JP (1) | JP2023548205A (enExample) |
| CN (1) | CN116802194A (enExample) |
| AR (1) | AR123998A1 (enExample) |
| AU (1) | AU2021373188A1 (enExample) |
| CA (1) | CA3197024A1 (enExample) |
| CO (1) | CO2023004963A2 (enExample) |
| CU (1) | CU24665B1 (enExample) |
| MX (1) | MX2023005211A (enExample) |
| WO (1) | WO2022096039A1 (enExample) |
| ZA (1) | ZA202304779B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7887978B2 (ja) * | 2022-05-23 | 2026-07-10 | バクスディグム カンパニー，リミティド | ウイルスヌクレオカプシドを用いた結晶性タンパク質ベースの標的タンパク質融合自己組織化ナノ粒子製造プラットフォーム |
| KR102617592B1 (ko) * | 2022-05-23 | 2023-12-29 | 주식회사 백스다임 | 바이러스 뉴클레오캡시드를 이용한 오량체형 독소 단백질 기반 목적 단백질 융합 오량체 제조 플랫폼 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| CN111366734B (zh) * | 2020-03-20 | 2021-07-13 | 广州市康润生物科技有限公司 | 双指标筛选新冠病毒及预判重型肺炎的方法 |
| CN111620952A (zh) * | 2020-06-17 | 2020-09-04 | 苏州米迪生物技术有限公司 | 基于嵌合型病毒样颗粒的新型冠状病毒疫苗 |
| CN111676248A (zh) * | 2020-07-02 | 2020-09-18 | 军事科学院军事医学研究院军事兽医研究所 | 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建 |
-
2020
- 2020-11-04 CU CU2020000081A patent/CU24665B1/es unknown
-
2021
- 2021-11-03 JP JP2023527114A patent/JP2023548205A/ja active Pending
- 2021-11-03 MX MX2023005211A patent/MX2023005211A/es unknown
- 2021-11-03 WO PCT/CU2021/050010 patent/WO2022096039A1/es not_active Ceased
- 2021-11-03 CA CA3197024A patent/CA3197024A1/en active Pending
- 2021-11-03 CN CN202180088951.7A patent/CN116802194A/zh active Pending
- 2021-11-03 EP EP21834711.0A patent/EP4242222A1/en active Pending
- 2021-11-03 US US18/035,254 patent/US20230405106A1/en active Pending
- 2021-11-03 AU AU2021373188A patent/AU2021373188A1/en not_active Abandoned
- 2021-11-04 AR ARP210103065A patent/AR123998A1/es unknown
-
2023
- 2023-04-20 CO CONC2023/0004963A patent/CO2023004963A2/es unknown
- 2023-04-25 ZA ZA2023/04779A patent/ZA202304779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023548205A (ja) | 2023-11-15 |
| CO2023004963A2 (es) | 2023-06-20 |
| CA3197024A1 (en) | 2022-05-12 |
| CU24665B1 (es) | 2023-06-13 |
| CU20200081A7 (es) | 2022-06-06 |
| AU2021373188A1 (en) | 2023-06-01 |
| CN116802194A (zh) | 2023-09-22 |
| AR123998A1 (es) | 2023-02-01 |
| US20230405106A1 (en) | 2023-12-21 |
| WO2022096039A1 (es) | 2022-05-12 |
| EP4242222A1 (en) | 2023-09-13 |
| AU2021373188A9 (en) | 2024-10-10 |
| MX2023005211A (es) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heidary et al. | A comprehensive review of the protein subunit vaccines against COVID-19 | |
| Rupp et al. | Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| JP2009537143A5 (enExample) | ||
| BR112022010425A2 (pt) | Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b | |
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| EA201500848A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ОБОГАЩЕННОЙ IgG-КОМПОЗИЦИИ ИЗ ПЛАЗМЫ | |
| NO20072733L (no) | Doseformer | |
| AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
| DK1326636T3 (da) | Vaccinesammensætning | |
| Dorfmeier et al. | Reinvestigating the role of IgM in rabies virus postexposure vaccination | |
| EA200970586A1 (ru) | Антитела к цитомегаловирусу человека (hcmv) | |
| GT200800269A (es) | Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina | |
| JP2018505882A5 (enExample) | ||
| MX2009000650A (es) | Vacunas para malaria. | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| Lu et al. | A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses | |
| JP2018510894A5 (enExample) | ||
| PH12021550441A1 (en) | Modified pedv spike protein | |
| MY206043A (en) | H52 ibv vaccine with heterologous spike protein | |
| CL2022002588A1 (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica. | |
| MX2023005211A (es) | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden. | |
| JP2025081437A5 (enExample) | ||
| BR0207988A (pt) | Cepas atenuadas vivas de vìrus de prrs | |
| AR081409A1 (es) | PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) |